The MONALEESA-7 and MONALEESA-2 trials of pre/perimenopausal and postmenopausal women, respectively, with HR+/HER2− advanced breast cancer and visceral metastasis have shown that ribociclib in combination with ET provided a significant PFS benefit compared with placebo in combination with ET (20, 21). Here, HR is linked to breast carcinoma.